Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory
We came across a bullish thesis on Fulcrum Therapeutics, Inc. (FULC) on Stock Pursuit’s Substack. In this article, we will summarize the bulls’ thesis on FULC.
Posts Tagged ‘NASDAQ:FULC’
Leerink Partners Upgrades Fulcrum Therapeutics, Inc. (FULC) to Outperform, Raises Price Target
The analyst cited a favorable risk-reward setup as the reason behind the upgrade, ahead of the trial readout for Pociredir, its lead clinical program, to treat sickle cell disease...
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2024 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2024 Earnings Call Transcript February 25, 2025Fulcrum Therapeutics, Inc. misses on earnings expectations.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Fulcrum Therapeutics Third Quarter 2024 Financial Results and Business Update Conference Call.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2024 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2024 Earnings Call Transcript July 31, 2024Fulcrum Therapeutics, Inc. beats earnings expectations.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2024 Earnings Call Transcript
Operator: Good morning and welcome to Fulcrum Therapeutics' First Quarter 2024 Financial Results and Business Update Conference Call.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript
Fulcrum Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.4, expectations were $-0.44.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2023 Earnings Call Transcript
Operator: Good morning and welcome to Fulcrum Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Fulcrum Therapeutics Second Quarter 2023 Financial Results and Business Update Conference Call.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Fulcrum Therapeutics First Quarter 2023 Financial Results and Business Update Conference Call.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2022 Earnings Call Transcript
Operator: Greetings, and welcome to Fulcrum Therapeutics Fourth Quarter and Full Year 2022 Earnings Conference Call. As a reminder, this conference is being recorded.
Hedge Funds Are Crazy About Fulcrum Therapeutics, Inc. (FULC)
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need ...
5 Biotech Stocks Popular On Reddit
In this article, we discuss the 5 biotech stocks popular on Reddit.
Were Hedge Funds Right About Fulcrum Therapeutics, Inc. (FULC)?
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade.
Is FULC A Good Stock To Buy Now?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end...
Do Hedge Funds Love Fulcrum Therapeutics, Inc. (FULC)?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the...
Hedge Funds Have Never Been This Bullish On Fulcrum Therapeutics, Inc. (FULC)
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could...
